Overview of Management of Myocardial Ischemia: a Mechanistic-Based Approach

Cardiovascular Drugs and Therapy

Volumn 30, Issue 4, 2016, Pages 341-349

  Lanza, Gaetano Antonio ^a   Crea, Filippo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Angina; Clinical outcome; Medical therapy; Myocardial ischemia; Pathophysiologic mechanisms

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; IVABRADINE; NICORANDIL; NITRIC ACID DERIVATIVE; RANOLAZINE; TRIMETAZIDINE; CARDIOVASCULAR AGENT;

ARTERY STEAL SYNDROME; ARTICLE; CARDIAC PATIENT; COLLATERAL CIRCULATION; HEART MUSCLE ISCHEMIA; HEART RATE; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; STABLE ANGINA PECTORIS; DRUG EFFECTS; MYOCARDIAL ISCHEMIA;

CARDIOVASCULAR AGENTS; HEART RATE; HUMANS; MYOCARDIAL ISCHEMIA;

EID: 84964334270     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-016-6662-5     Document Type: Article

References (72)

1. Klocke FJ. Measurements of coronary blood flow and degree of stenosis: current clinical implications and continuing uncertainties. J Am Coll Cardiol. 1983;1:31–41.
2. Di Carli M, Czernin J, Hoh CK, et al. Relation among stenosis severity, myocardial blood flow, and flow reserve in patients with coronary artery disease. Circulation. 1995;91:1944–51.
3. JM JC. Coronary pressure-function and steady-state pressure-flow relations during autoregulation in the unanesthetized dog. Circ Res. 1988;63:821–36.
4. Tousoulis D, Crake T, Kaski JC, et al. Enhanced vasomotor responses of complex coronary stenoses to acetylcholine in stable angina pectoris. Am J Cardiol. 1995;75:725–8.
5. Panza JA, Epstein SE, Quyyumi AA. Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity. N Engl J Med. 1991;325:986–90.
6. Sambuceti G, Marzilli M, Fedele S, Marini C, L'Abbate A. Paradoxical increase in microvascular resistance during tachycardia downstream from a severe stenosis in patients with coronary artery disease: reversal by angioplasty. Circulation. 2001;103:2352–60.
7. Pupita G, Maseri A, Kaski JC, et al. Myocardial ischemia caused by distal coronary-artery constriction in stable angina pectoris. N Engl J Med. 1990;323:514–20.
8. Hamasaki S, Arima S, Fukumoto N, et al. Mechanisms of limited maximum coronary flow in severe single-vessel coronary artery disease in humans due to vertical steal. Am J Cardiol. 1997;80:1597–601.
9. Holmvang G, Fry S, Skopicki HA, Abraham SA, et al. Relation between coronary "steal" and contractile function at rest in collateral-dependent myocardium of humans with ischemic heart disease. Circulation. 1999;99:2510–6.
10. Lalonde F, Poirier P, Sylvestre MP, Arvisais D, Curnier D. Exercise-induced ischemic preconditioning and the potential application to cardiac rehabilitation: a systematic review. Eur J Prev Cardiol. 2015;22:100–12.
11. Matsuzaki M, Patritti J, Tajimi T, Miller M, Kemper WS, Ross J. Effects of beta-blockade on regional myocardial flow and function during exercise. Am J Phys. 1984;247(1 Pt 2):H52–60.
12. Guth BD, Heusch G, Seitelberger R, Matsuzaki M, Ross J Jr. Role of heart rate reduction in the treatment of exercise-induced myocardial ischaemia. Eur Heart J. 1987; 8(Suppl L):61–8.
13. Pepine CJ, Hill JA, Imperi GA, Norvell N. Beta-adrenergic blockers in silent myocardial ischemia. Am J Cardiol. 1988;61:18B–21B.
14. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet. 1981;2:823–7.
15. Pedersen T. The Norwegian multicenter study on timolol after myocardial infarction - design, management and results on mortality. Acta Med Scand (Suppl). 1981;651:235–41.
16. Pepine CJ, Cohn PF, Deedwania PC, et al. Circulation. effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. the atenolol silent ischemia study (ASIST). Circulation. 1994;90:762–8.
17. DAVIT study group. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish verapamil infarction trial II–DAVIT II). Am J Cardiol. 1990;66:779–85.
18. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319:385–92.
19. Boden WE, van Gilst WH, Scheldewaert RG, et al. Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. incomplete infarction trial of European Research Collaborators Evaluating prognosis post-Thrombolysis (INTERCEPT). Lancet. 2000;355:1751–6.
20. Arnman K, Rydén L. Comparison of metoprolol and verapamil in the treatment of angina pectoris. Am J Cardiol. 1982;49:821–7.
21. Brouwer J, Viersma JW, van Veldhuisen DJ, et al. Efficacy of metoprolol and diltiazem in treating silent myocardial ischemia. Am J Cardiol. 1995;76:759–63.
22. Rehnqvist N, Hjemdahl P, Billing E, et al. Effects of metoprolol versus verapamil treatment in patients with stable angina pectoris-the angina prognosis study In Stockholm (APSIS). Eur Heart J. 1996;17:76–81.
23. Heidenreich PA, McDonald KM, Hastie T, et al. Meta-analysis oftrials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA. 1999;281:1927–36.
24. Di Francesco D. I (f) inhibition: a novel mechanism of action. Eur Heart J. 2003;5(suppl G):G19–25.
25. Borer JS, Fox K, Jaillon P, Lerebours G, Group II. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107:817–23.
26. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K, Investigators INITIATIVE. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26:2529–36.
27. Tardif JC, Ponikowski P, Kahan T, Study Investigators ASSOCIATE. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009;30:540–8.
28. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008;372:817–21.
29. Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R, Investigators SIGNIFY. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371:1091–9.
30. Dargie HJ, Ford I, Fox KM, on behalf of the TIBET Study Group. Total lschaemic burden European trial (TIBET): effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome. Eur Hean J. 1996;17:104–12.
31. Savonitto S, Ardissiono D, Egstrup K, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. results of the International multicenter angina exercise (IMAGE) study. J Am Coll Cardiol. 1996;27:311–6.
32. von Arnim T. Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. the TIBBS Investigators. J Am Coll Cardiol. 1995;25:231–8.
33. Poole-Wilson PA, Kirwan BA, Vokó Z, de Brouwer S, van Dalen FJ, Lubsen J, Investigators ACTION. Safety of nifedipine GITS in stable angina: the ACTION trial. Cardiovasc Drugs Ther. 2006;20:45–54.
34. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217–25.
35. De Mots H, Glasser SP. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cardiol. 1989;13:786–95.
36. Chrysant SG, Glasser SP, Bittar N, et al. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris. Am J Cardiol. 1993;72:1249–56.
37. Markham A, Plosker GL, Goa KL. Nicorandil. an updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects. Drugs. 2000;60:955–74.
38. Rajaratnam R, Brieger DB, Hawkins R, et al. Attenuation of anti-ischemic efficacy during chronic therapy with nicorandil in patients with stable angina pectoris. Am J Cardiol. 1999;83:1120–4.
39. Doring G. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients. J Cardiovasc Pharmacol. 1992;20(Suppl 3):S74–81.
40. Di Somma S, Liguori V, Petitto M, et al. A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris. Cardiovasc Drugs Ther. 1993;7:119–23.
41. IONA trial. Effect of nicorandil on coronary events in patients with stable angina: the impact of nicorandil in angina (IONA) randomised trial. Lancet. 2002;359:1269–75.
42. Nash DT, Nash SD. Ranolazine for chronic stable angina. Lancet. 2008;372:1335–41.
43. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43:1375–82.
44. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291:309–16.
45. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L, Investigators ERICA. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (efficacy of ranolazine in chronic angina) trial. J Am Coll Cardiol. 2006;48:566–75.
46. Weisz G, Généreux P, Iñiguez A, et al. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387:136–45.
47. Alexander KP, Weisz G, Prather K, et al. Effects of ranolazine on angina and quality of life after percutaneous coronary intervention with incomplete revascularization: results from the ranolazine for incomplete vessel revascularization (RIVER-PCI) trial. Circulation. 2016;133:39–47.
48. Stanley WC, Marzilli M. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine. Fundam Clin Pharmacol. 2003;17:133–45.
49. Peng S, Zhao M, Wan J, Fang Q, Fang D, Li K. The efficacy of trimetazidine on stable angina pectoris: a meta-analysis of randomized clinical trials. Int J Cardiol. 2014;177:780–5.
50. Cohn PF, Fox KM, Daly C. Silent myocardial ischemia. Circulation. 2003;108:1263–77.
51. Gibbons RJ, Mller TD. Is ischemia dead after STICH? J Am Coll Cardiol. 2013;61:1871–3.
52. Gottlieb SO, Sidney O. M.D. Weisfeldt, et al. silent ischemia as a marker for early unfavorable outcomes in patients with unstable angina. N Engl J Med. 1986;314:1214–9.
53. Gill JB, Cairns JA, Roberts RS, et al. Prognostic importance of myocardial ischemia detected by ambulatory monitoring early after acute myocardial infarction. N Engl J Med. 1996;334:65–71.
54. Weiner DA, Ryan T, McCabe C, et al. Prognostic importance of a clinical profile and exercise test in medically treated patients with coronary artery disease. J Am Coll Cardiol. 1984;3:772–7.
55. Prakash M, Myers J, Froelicher VF, et al. Clinical and exercise test predictors of all cause mortality. Chest. 2001;120:1003–13.
56. Weiner DA, Ryan TJ, McCabe CH, et al. Significance of silent myocardial ischemia during exercise testing in patients with coronary artery disease. Am J Cardiol. 1987;59:725–9.
57. Thompson C, Jabbour S, Goldberg R, et al. Exercise performance based outcomes of medically treated patients with coronary artery disease and profound ST depression. J Am Coll Cardiol. 2000;36:2140–5.
58. Lauer MS, Pothier CE, Magid DJ, Smith SS, Kattan MW. An externally validated model for predicting long-term survival after exercise treadmill testing in patients with suspected coronary artery disease and a normal electrocardiogram. Ann Intern Med. 2007;147:821–8.
59. Pepine CJ, Sharaf B, Andrews TC, et al. Relation between clinical, angiographic and ischemic findings at baseline and ischemia-related adverse outcomes at 1 year in the asymptomatic cardiac ischemia Pilot study. ACIP study group. J Am Coll Cardiol. 1997;29:1483–9.
60. Mulcahy D, Knight C, Patel D, et al. Detection of ambulatory ischaemia is not of practical clinical value in the routine management of patients with stable angina: a long-term follow-up study. Eur Heart J. 1995;16:317–24.
61. Gandhi MM, Wood DA, Lampe F. Characteristics and clinical significance of ambulatory myocardial ischemia in men and women in the general population presenting with angina pectoris. J Am Coll Cardiol. 1994;23:74–81.
62. Hausmann D, Nikutta P, Trappe HJ, Daniel WG, Wenzlaff P, Lichtlen PR. Incidence of ventricular arrhythmias during transient myocardial ischemia in patients with stable coronary artery disease. J Am Coll Cardiol. 1990;16:49–54.
63. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management Of Patients With Stable Ischemic Heart Disease. J Am Coll Cardiol. 2012;60:e44–e164.
64. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J. 2013;34:2949–3003.
65. Rogers WJ, Bourassa MG, Andrews TC, et al. Asymptomatic cardiac ischemia Pilot (ACIP) study: outcome at 1 year for patients with asymptomatic cardiac ischemia randomized to medical therapy or revascularization. the ACIP Investigators. J Am Coll Cardiol. 1995;26:594–605.
66. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the coronary artery bypass graft surgery Trialists Collaboration. Lancet. 1994;344:563–70.
67. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–16.
68. The BARI. 2D study group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503–15.
69. Velazquez EJ, Lee KL, Deja MA, Jain A, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364:1607–16.
70. ClinicalTrials.gov. International study of comparative health effectiveness with medical and invasive approaches (ISCHEMIA). https://clinicaltrials.gov/ct2/show/NCT01471522. Accessed 20 Dec 2014.
71. Crea F, Camici PG, De Caterina R, Lanza GA. Chronic ischaemic heart disease. In: The ESC textbook of cardiovascular medicine. Oxford; 2009. p. 597–664.
72. Andrews TC, Fenton T, Toyosaki N, et al. Subsets of ambulatory myocardial ischemia based on heart rate activity. Circadian distribution and response to anti-ischemic medication. The angina and silent ischemia study group (ASIS). Circulation. 1993;8:92–100.